Identification Generic Name (13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE DrugBank Accession Number DB06888 Background Not Available Type Small Molecule Groups Experimental Structure 
 
 
 3D Download  MOL SDF 3D-SDF PDB SMILES InChI 
 
 
  Similar Structures Structure for (13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE (DB06888) ×  Close Weight Average: 403.4338  Monoisotopic: 403.164439563  Chemical Formula C 22 H 21 N 5 O 3 Synonyms Not Available Pharmacology Indication Not Available Reduce drug development failure rates Build, train, & validate machine-learning models with evidence-based and structured datasets. See how     Build, train, & validate predictive machine-learning models with structured datasets. See how Contraindications & Blackbox Warnings Avoid life-threatening adverse drug events Improve clinical decision support with information on  contraindications & blackbox warnings, population restrictions, harmful risks, & more. Learn more     Avoid life-threatening adverse drug events & improve clinical decision support. Learn more Pharmacodynamics Not Available Mechanism of action Target Actions Organism U Cyclin-dependent kinase 2 Not Available Humans Absorption Not Available Volume of distribution Not Available Protein binding Not Available Metabolism Not Available Route of elimination Not Available Half-life Not Available Clearance Not Available Adverse Effects Improve decision support & research outcomes With structured adverse effects data, including:  blackbox warnings, adverse reactions, warning & precautions, & incidence rates. Learn more     Improve decision support & research outcomes with our structured adverse effects data. Learn more Toxicity Not Available Pathways Not Available Pharmacogenomic Effects/ADRs  
 
 
 Not Available Interactions Drug Interactions  
 
 
 This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.  Not Available Food Interactions Not Available Categories Drug Categories Not Available Chemical Taxonomy Provided by  Classyfire Description This compound belongs to the class of organic compounds known as quinoxalines. These are compounds containing a quinoxaline moiety, a bicyclic heterocycle made up of a benzene ring fused to a pyrazine ring. Kingdom Organic compounds Super Class Organoheterocyclic compounds Class Diazanaphthalenes Sub Class Benzodiazines Direct Parent Quinoxalines Alternative Parents Indazoles  /  Alkyl aryl ethers  /  Pyrazolones  /  Pyrazines  /  N-alkylpyrrolidines  /  Benzenoids  /  Vinylogous amides  /  Pyrazoles  /  Heteroaromatic compounds  /  Trialkylamines  /  Lactams  /  Oxacyclic compounds  /  Azacyclic compounds  /  Hydrocarbon derivatives  /  Organic oxides  /  Organopnictogen compounds 
 
 
  show 6 more Substituents Alkyl aryl ether  /  Amine  /  Aromatic heteropolycyclic compound  /  Azacycle  /  Azole  /  Benzenoid  /  Benzopyrazole  /  Ether  /  Heteroaromatic compound  /  Hydrocarbon derivative  /  Indazole  /  Lactam  /  N-alkylpyrrolidine  /  Organic nitrogen compound  /  Organic oxide  /  Organic oxygen compound  /  Organonitrogen compound  /  Organooxygen compound  /  Organopnictogen compound  /  Oxacycle  /  Pyrazine  /  Pyrazole  /  Pyrazolinone  /  Pyrrolidine  /  Quinoxaline  /  Tertiary aliphatic amine  /  Tertiary amine  /  Vinylogous amide 
 
 
  show 18 more Molecular Framework Aromatic heteropolycyclic compounds External Descriptors Not Available Affected organisms Not Available Chemical Identifiers UNII Not Available CAS number Not Available InChI Key KBLPHMRCKHFBJB-OLZOCXBDSA-N InChI InChI=1S/C22H21N5O3/c1-12-10-13-11-26(12)8-9-27-22(29)15-5-2-4-14(18(15)25-27)19-21(28)23-16-6-3-7-17(30-13)20(16)24-19/h2-7,12-13,25H,8-11H2,1H3,(H,23,28)/t12-,13+/m1/s1 IUPAC Name (13R,15S)-13-methyl-16-oxa-8,9,12,22,24-pentaazahexacyclo[15.6.2.1^{6,9}.1^{12,15}.0^{2,7}.0^{21,25}]heptacosa-1(24),2(7),3,5,17,19,21(25)-heptaene-23,27-dione SMILES [H][C@]12CN(CCN3NC4=C(C=CC=C4C3=O)C3=NC4=C(NC3=O)C=CC=C4O1)[C@]([H])(C)C2 References General References Not Available External Links PubChem Compound 16046126 PubChem Substance 99443359 ChemSpider 13174538 BindingDB 50192071 ZINC ZINC000003820290 PDBe Ligand 1CD PDB Entries 2ds1 Clinical Trials Clinical Trials  
 
 
 Phase Status Purpose Conditions Count Pharmacoeconomics Manufacturers Not Available Packagers Not Available Dosage Forms Not Available Prices Not Available Patents Not Available Properties State Solid Experimental Properties Not Available Predicted Properties Property Value Source Water Solubility 0.335 mg/mL ALOGPS logP 1.86 ALOGPS logP 2.14 Chemaxon logS -3.1 ALOGPS pKa (Strongest Acidic) 8.57 Chemaxon pKa (Strongest Basic) 7.9 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 86.27 Å 2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 116.32 m 3 ·mol -1 Chemaxon Polarizability 42.01 Å 3 Chemaxon Number of Rings 6 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon Predicted ADMET Features Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.7265 Caco-2 permeable - 0.6081 P-glycoprotein substrate Substrate 0.8071 P-glycoprotein inhibitor I Non-inhibitor 0.5129 P-glycoprotein inhibitor II Non-inhibitor 0.9302 Renal organic cation transporter Non-inhibitor 0.6758 CYP450 2C9 substrate Non-substrate 0.8791 CYP450 2D6 substrate Non-substrate 0.6851 CYP450 3A4 substrate Substrate 0.6624 CYP450 1A2 substrate Non-inhibitor 0.8396 CYP450 2C9 inhibitor Non-inhibitor 0.8381 CYP450 2D6 inhibitor Non-inhibitor 0.7095 CYP450 2C19 inhibitor Non-inhibitor 0.6885 CYP450 3A4 inhibitor Non-inhibitor 0.9182 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7216 Ames test AMES toxic 0.5277 Carcinogenicity Non-carcinogens 0.7898 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.6409 LD50, mol/kg  Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7555 hERG inhibition (predictor II) Non-inhibitor 0.6733    ADMET data is predicted using  admetSAR , a free tool for evaluating chemical ADMET properties. ( 23092397 )  Spectra Mass Spec (NIST) Not Available Spectra Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available Targets Build, predict & validate machine-learning models Use our structured and evidence-based datasets to  unlock newinsights and accelerate drug research. Learn more     Use our structured and evidence-based datasets to unlock new insights and accelerate drug research. Learn more Binding Properties × Property Measurement pH Temperature (°C) References IC 50 (nM) 3.4 N/A N/A A30693 
 
 
  Details 
 
 
   Binding Properties 1.  Cyclin-dependent kinase 2 Kind Protein Organism Humans Pharmacological action Unknown General Function Metal ion binding Specific Function Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, N... Gene Name CDK2 Uniprot ID P24941 Uniprot Name Cyclin-dependent kinase 2 Molecular Weight 33929.215 Da References Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [ Article ]  × Identify potential medication risks Easily compare up to 40 drugs with our drug interaction checker. Get severity rating, description, and management advice.  Learn more      Drug created at September 15, 2010 21:17 / Updated at June 12, 2020 16:52 